OnKure Secures $150M, Advances OKI-355 and OKI-345 Candidates
OnKure closed a $150 million private placement, boosting cash to $192.1 million as of March 31, 2026, to fund operations into 2029. The company nominated two next-generation PI3Kα pan-mutant inhibitors—OKI-355 for vascular anomalies and OKI-345 for breast cancer—with IND applications planned in H1 2027.
1. First Quarter 2026 Financial Results
OnKure reported R&D expenses of $11.7 million for Q1 2026 versus $13.0 million in Q1 2025 and G&A expenses of $3.9 million down from $4.0 million year-over-year. The net loss narrowed to $15.2 million, or $1.11 per share, compared to $15.9 million, or $1.19 per share, in the prior year period.
2. $150 Million Private Placement and Cash Position
The company closed an oversubscribed $150 million private placement on March 31, 2026, bringing cash and cash equivalents to $192.1 million. Management expects this capital will fund current operations into 2029 without dilution.
3. Nomination of Next-Generation PI3Kα Pan-Mutant Inhibitors
OnKure nominated OKI-355, designed for mutant PI3Kα selectivity in vascular anomalies, and OKI-345, for similar selectivity in breast cancer. Both candidates are engineered to spare wild-type PI3Kα, potentially widening the therapeutic index and reducing class-related toxicities.
4. IND Submission Timeline and Strategic Focus
The company plans to submit Investigational New Drug applications for OKI-355 and OKI-345 in the first half of 2027. In light of its focus on pan-mutant inhibitors, OnKure will not advance OKI-219 independently and aims to report PIKture-01 data by year-end 2026.